Lipocine Inc (LPCN) - Total Liabilities
Based on the latest financial reports, Lipocine Inc (LPCN) has total liabilities worth $2.53 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Lipocine Inc to track the company's year-over-year net asset growth rate.
Lipocine Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Lipocine Inc's total liabilities have evolved over time, based on quarterly financial data. See LPCN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Lipocine Inc Competitors by Total Liabilities
The table below lists competitors of Lipocine Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MMAG Holdings Bhd
KLSE:0034
|
Malaysia | RM534.48 Million |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
USA | $238.96 Million |
|
Galileo Mining Ltd
AU:GAL
|
Australia | AU$540.25K |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$4.68 Million |
|
SDN Company. Ltd
KQ:099220
|
Korea | ₩80.33 Billion |
|
Aerometrex Ltd
AU:AMX
|
Australia | AU$24.84 Million |
|
Bravada Gold Corporation
V:BVA
|
Canada | CA$1.39 Million |
|
Ennogie Solar Group A/S
CO:ESG
|
Denmark | Dkr57.10 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Lipocine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Lipocine Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lipocine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lipocine Inc (2011–2025)
The table below shows the annual total liabilities of Lipocine Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.53 Million | +67.11% |
| 2024-12-31 | $1.51 Million | -42.51% |
| 2023-12-31 | $2.63 Million | +37.93% |
| 2022-12-31 | $1.91 Million | -72.40% |
| 2021-12-31 | $6.91 Million | -30.95% |
| 2020-12-31 | $10.01 Million | -25.13% |
| 2019-12-31 | $13.37 Million | +17.10% |
| 2018-12-31 | $11.42 Million | +79.95% |
| 2017-12-31 | $6.35 Million | +378.46% |
| 2016-12-31 | $1.33 Million | -60.90% |
| 2015-12-31 | $3.39 Million | +107.64% |
| 2014-12-31 | $1.63 Million | +27.24% |
| 2013-12-31 | $1.28 Million | +10694.37% |
| 2012-12-31 | $11.89K | +56.38% |
| 2011-12-31 | $7.61K | -- |
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1… Read more